Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-06-18

Clinical Trial Update: Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria [Phase 3]

View source ↗

Summary

Phase 3 trial update discusses the efficacy and safety of omalizumab for chronic idiopathic urticaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xolair (omalizumab)

Snippet

Sponsor: Rabin Medical Center | Conditions: Chronic Idiopathic Urticaria | Phase 3 | Status: UNKNOWN